Last month, Merck & Co., Inc.’s Winrevair (sotatercept) became the first disease-modifying therapy approved for pulmonary arterial hypertension (PAH) and expectations for the product are high, with equity analysts seeing it attaining blockbuster sales by 2026. But there are several products in development for this rare disease whose developers are hoping to give Merck a run for its money.
Key Takeaways
- Merck & Co’s Winrevair leads the pulmonary arterial hypertension market with forecast 2028 sales of $2
In terms of late-stage readouts, the most immediate threat to Merck comes from United Therapeutics Corporation, an already entrenched PAH player with two further products in Phase III